Navigation Links
Angioslide Announces FDA 510(K) Clearance of PROTEUS(TM) Below The Knee Device
Date:5/2/2012

CAESAREA, Israel, May 2, 2012 /PRNewswire/ --

Angioslide Ltd. a provider of Embolic Capture Angioplasty solutions, today announced that it has received FDA 510(K) clearance for its new 3X100mm PROTEUS device for treating Peripheral Artery Disease in below the knee (BTK) vasculature.  The new 3/100mm device accommodates 0.014" guide-wires, which significantly broadens the potential use of PROTEUS technology.  

Angioslide's proprietary technology combines the functionality of a balloon angioplasty device with the addition of built-in embolic capture. PROTEUS is a competitive PTA (Percutaneous Transluminal Angioplasty) balloon with features similar to leading PTA balloons (deflation time, pushability, crossing profile). Then, during deflation, the PROTEUS captures and retrieves potentially harmful embolic material.  The capture of embolic material is enabled by the inward folding of the balloon, which creates a low pressure cavity. The negative pressure in this cavity generates an aspiration effect, pulling embolic material into the cavity.  When retrieved through the sheath, PROTEUS removes the captured material from the body.

Below-the-Knee (BTK) interventions are often characterized by patients with long and diffuse lesions, diabetic foot ulcers and/or Critical Limbs Ischemia (CLI).  PROTEUS 3X100 offers physicians, for the first time, the ability to capture and remove embolic material with a single device during these challenging interventions.    

"Introduction of the new dedicated, BTK, low-profile 0.014" PROTEUS platform, supports Angioslide continuing commitment to improve procedure outcomes. Distal embolic complications in this compromised group of patients further risk blood flow to the foot. PROTEUS will become a necessary device in the "tool-box" of physicians practicing "endovascular-first" approach," said Lihu Avitov, Angioslide CEO.  

About Angioslide

Founded in 2005, Angioslide is a privately held medical device company that developed a unique Embolic Capture Angioplasty solution, PROTEUS™, which provides a combination of PTA balloon and embolic capture. The PROTEUS™ device addresses an unmet need for an easy-to-use, efficient and cost-effective embolic particle capture solution for the peripheral vascular disease market. It is the first device of its kind to receive FDA clearance for use in lower limbs. The device has also received European CE Mark approval for lower limb use and is being marketed in selected regions in Europe. Angioslide headquarters are located in Caesarea, Israel, and Denver Colorado.  For more information visit our website at http://www.angioslide.com

Contact:
Shira Doron
Marketing Director
Mobile: +972-54-9011134
shirad@angioslide.com

 



'/>"/>
SOURCE Angioslide Ltd.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Angioslide Announces the European Launch of New 300 mm Long Device Allowing Treatment of Entire Superficial Femoral Artery(SFA) with One Device
2. Angioslide Commercializes in the U.S. First Device to Combine Balloon Angioplasty and Embolic Capture
3. Hill-Rom Announces Third Quarter 2012 Dividend
4. Trovagene Announces Plans to Develop Proprietary Test for High Risk HPV Carrier Screening from Urine
5. Medical Guardian Announces Social Media Partnership with Senior Citizen Charity
6. The Law Firm of Levi & Korsinsky, LLP Announces Investigation into Possible Breaches of Fiduciary Duty by the Board of Gen-Probe Incorporated in Connection with the Sale of the Company to Hologic, Inc.
7. ConvaTec Announces Acquisition of AbViser Medical, LLC
8. Cardica Announces Fiscal 2012 Third Quarter Financial Results
9. Arena Pharmaceuticals Announces First Quarter 2012 Financial Results and Recent Developments
10. Ultragenyx Announces Phase 1 Results of UX001 in Hereditary Inclusion Body Myopathy (HIBM), a Rare Neuromuscular Disease
11. Acella Pharmaceuticals Announces a New Addition to the Commercial Team
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... , February 9, 2016 ... announced a collaboration with 10x Genomics to develop ... single-cell biology and bioinformatics. --> QGEN ... collaboration with 10x Genomics to develop and promote ... and bioinformatics. --> QIAGEN N.V. (NASDAQ: ...
(Date:2/9/2016)... 9, 2016 Mast Therapeutics, Inc. (NYSE ... sickle cell disease and heart failure, today announced that it ... purchase common stock in an underwritten public offering.  The offering ... be no assurance as to whether or when the offering ... terms of the offering.   --> ...
(Date:2/9/2016)... FRANCISCO , February 9, 2016 ... biotechnology company focused on developing products for Regenerative Medicine, ... be a featured presenting company at Source Capital Group,s ... on February 10-11, 2016 in New York ... on Wednesday, February 10, 2016 at 12:30 pm by ...
Breaking Medicine Technology:
(Date:2/10/2016)... ... February 10, 2016 , ... For additional information contact Phyllis Strupp 480-488-5858 , ... with Age: The Ultimate Guide to Brain Training" by award-winning author Phyllis Strupp ... publication date is March 16, 2016. A free review copy is available to ...
(Date:2/10/2016)... ... February 10, 2016 , ... Everseat has joined ... readily available to physicians. The integration will enable Allscripts users to post open ... Everseat’s free mobile app. , The partnership gives Everseat substantial added power to ...
(Date:2/10/2016)... ... February 10, 2016 , ... Workrite Ergonomics this week announced the launch ... mounts ever. , “Our goal was to develop a product from the ground ... we have ever created.” said Darren Hulsey, Product Manager for Workrite Ergonomics. “The ...
(Date:2/10/2016)... ... ... Anxiety of older Americans over steep cost increases of prescription drugs is at ... to The Senior Citizens League (TSCL). Since last fall, TSCL has ... costs. “The implications are chilling, particularly for people with chronic health problems,” says ...
(Date:2/10/2016)... ... 09, 2016 , ... Ross A. Clevens, MD, FACS ... welcome a new addition to their growing practice. Beginning this month, Teresa Imperiale-Westerfield, ... practitioner performing cosmetic procedures including injectables, fillers and laser treatments. A ...
Breaking Medicine News(10 mins):